Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT

Theranostics

Volumn 6, Issue 2, 2016, Pages 262-271

  Sörensen, Jens ^a   Velikyan, Irina ^a   Sandberg, Dan ^a   Wennborg, Anders ^b   Feldwisch, Joachim ^a,b   Tolmachev, Vladimir ^a   Orlova, Anna ^a   Sandström, Mattias ^a   Lubberink, Mark ^a   Olofsson, Helena ^a,c   Carlsson, Jörgen ^a   Lindman, Henrik ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

68Ga gallium; Affibody; Breast cancer metastases; Clinical study; HER2 receptor

Indexed keywords

ABY 025 GA 68; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB; UNCLASSIFIED DRUG; 68GA-ABY-025; ABY-025; ERBB2 PROTEIN, HUMAN; GALLIUM; PEPTIDE FRAGMENT; PROTEIN BINDING; STAPHYLOCOCCUS PROTEIN A;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOACCUMULATION; BREAST CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIURESIS; DRUG SAFETY; DRUG TRANSPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; ISOTOPE LABELING; METASTASIS POTENTIAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; PRURITUS; SIDE EFFECT; TEST RETEST RELIABILITY; TREATMENT WITHDRAWAL; BREAST TUMOR; CASE CONTROL STUDY; CHEMISTRY; DIAGNOSTIC IMAGING; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GALLIUM RADIOISOTOPES; HUMANS; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; STAPHYLOCOCCAL PROTEIN A; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84954520777     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.13502     Document Type: Article

References (32)

1. [Internet] Globocan.iarc. Fact Sheets by Cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
2. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31: 3997-4013.
3. Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014; 79: 34-74.
4. Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30: 1594-600.
5. Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysis. Breast Cancer Res Treat. 2011; 129: 659-74.
6. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783-91.
7. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-92.
8. Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. European journal of cancer. 2014; 50: 277-89.
9. Wilking U, Karlsson E, Skoog L, Hatschek T, Lidbrink E, Elmberger G, et al. HER2 status in a population-derived breast cancer cohort: discordances during tumor progression. Breast Cancer Res Treat. 2011; 125: 553-61.
10. Foukakis T, Astrom G, Lindstrom L, Hatschek T, Bergh J. When to order a biopsy to characterise a metastatic relapse in breast cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2012; 23 Suppl 10: x349-53.
11. Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirstrom K, Bergh J, et al. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events. European journal of cancer. 2014; 50: 517-24.
12. Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. Journal of clinical oncology. 2012; 30: 2601-8.
13. Corcoran EB, Hanson RN. Imaging EGFR and HER2 by PET and SPECT: A Review. Medicinal Research Reviews. 2014; 34: 596-643.
14. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clinical pharmacology and therapeutics. 2010; 87: 586-92.
15. Beylergil V, Morris PG, Smith-Jones PM, Modi S, Solit D, Hudis CA, et al. Pilot study of 68Ga-DOTA-F(ab')2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications. 2013; 34: 1157-65.
16. Ahlgren S, Orlova A, Wallberg H, Hansson M, Sandstrom M, Lewsley R, et al. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. Journal of nuclear medicine. 2010; 51: 1131-8.
17. Eigenbrot C, Ultsch M, Dubnovitsky A, Abrahmsen L, Hard T. Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A. 2010; 107: 15039-44. doi:10.1073/pnas.1005025107.
18. Feldwisch J, Tolmachev V, Lendel C, Herne N, Sjoberg A, Larsson B, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol. 2010; 398: 232-47.
19. Sorensen J, Sandberg D, Sandstrom M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. Journal of nuclear medicine. 2014; 55: 730-5.
20. Tolmachev V, Wallberg H, Sandstrom M, Hansson M, Wennborg A, Orlova A. Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels. European journal of nuclear medicine and molecular imaging. 2011; 38: 531-9.
21. Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours-impact of peptide mass. Nucl Med Biol. 2010; 37: 265-75.
22. Tolmachev V, Velikyan I, Sandstrom M, Orlova A. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. European journal of nuclear medicine and molecular imaging. 2010; 37: 1356-67.
23. Velikyan I, Beyer GJ, Langstrom B. Microwave-supported preparation of 68Ga-bioconjugates with high specific radioactivity. Bioconjugate Chem. 2004; 15: 554-60.
24. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, et al. Targeted therapy in breast cancer: the HER-2/neu gene and protein. Molecular & cellular proteomics: MCP. 2004; 3: 379-98.
25. Pai-Scherf LH, Villa J, Pearson D, Watson T, Liu E, Willingham MC, et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clinical cancer research. 1999; 5: 2311-5.
26. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. European journal of cancer. 1999; 35: 1773-82.
27. Bates M, Sperinde J, Kostler WJ, Ali SM, Leitzel K, Fuchs EM, et al. Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Annals of oncology. 2011; 22: 2014-20.
28. Baum RP, Prasad V, Muller D, Schuchardt C, Orlova A, Wennborg A, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled affibody molecules. Journal of nuclear medicine. 2010; 51: 892-7.
29. Lam K, Scollard DA, Chan C, Levine MN, Reilly RM. Kit for the preparation of In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). Applied radiation and isotopes. 2014; 95C: 135-42.
30. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Current pharmaceutical design. 2008; 14: 2999-3019.
31. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? Journal of nuclear medicine. 2005; 46: 1940-5.
32. McLarty K, Cornelissen B, Scollard DA, Done SJ, Chun K, Reilly RM. Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. European journal of nuclear medicine and molecular imaging. 2009; 36: 81-93.